The research company Chosa Oncology increased its loss in the second quarter while taking several steps toward the commercialisation of Platin-DRP and, after the end of the period, strengthening its cash position through the exercise of warrants.The Group's other operating income amounted to SEK 0 (0).Operating loss amounted to SEK 2.8 million (2.1).Loss after financial items amounted to SEK 2.6 million (2.0). The loss for the period amounted to SEK 2.6 million (2.0).Loss per share after dilution amounted to SEK 0.03 (0.028).Cash and cash equivalents amounted to SEK 2.6 million at the end of June (1.9). The equity ratio was 91 percent (88).During the quarter, Chosa presented data at ASCO which, according to the company, showed that Platin-DRP significantly predicted overall survival in a phase III lung cancer study. The company also presented data from the I-SPY2 breast cancer study, where combined biomarkers for platinum and taxane identified patient groups with up to 78 percent pathological complete response.CEO Peter Buhl Jensen states that the company is now moving from clinical validation towards broader clinical use and commercialisation. Chosa has established a presence in Kendall Square in Boston and, after the end of the period, appointed Bill Cronin to lead business development and commercialisation in the United States.After the end of the period, 3,577,285 warrants of series TO2 were exercised, corresponding to approximately 45 percent of the outstanding warrants. This provides the company with approximately SEK 2.8 million before transaction costs.The company is not providing a financial forecast. The focus is on partnerships, commercialisation of Platin-DRP and continued validation in, among other areas, lung and breast cancer.Key figures, SEK millionQ2 2026Q2 2025Year-over-year changeOther operating income0.00.0-Operating loss-2.8-2.1-Net loss-2.6-2.0-Earnings per share, SEK-0.03-0.028-Cash and cash equivalents2.61.9+36.5%